These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21208844)

  • 1. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
    Messersmith WA; Jimeno A; Jacene H; Zhao M; Kulesza P; Laheru DA; Kahn Y; Spira A; Dancey J; Iacobuzio-Donahue C; Donehower RC; Carducci M; Rudek MA; Hidalgo M
    Clin Colorectal Cancer; 2010 Dec; 9(5):297-304. PubMed ID: 21208844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
    Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    Giantonio BJ; Catalano PJ; Meropol NJ; O'Dwyer PJ; Mitchell EP; Alberts SR; Schwartz MA; Benson AB;
    J Clin Oncol; 2007 Apr; 25(12):1539-44. PubMed ID: 17442997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
    Tsimberidou AM; Fu S; Ng C; Lim JA; Wen S; Hong D; Wheler J; Bedikian AY; Eng C; Wallace M; Camacho LH; Kurzrock R
    Cancer; 2010 Sep; 116(17):4086-94. PubMed ID: 20564148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
    Meyerhardt JA; Stuart K; Fuchs CS; Zhu AX; Earle CC; Bhargava P; Blaszkowsky L; Enzinger P; Mayer RJ; Battu S; Lawrence C; Ryan DP
    Ann Oncol; 2007 Jul; 18(7):1185-9. PubMed ID: 17483115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
    Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
    Madajewicz S; Waterhouse DM; Ritch PS; Khan MQ; Higby DJ; Leichman CG; Malik SK; Hentschel P; Gill JF; Zhao L; Nicol SJ
    Invest New Drugs; 2012 Apr; 30(2):772-8. PubMed ID: 21120580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
    Emmanouilides C; Sfakiotaki G; Androulakis N; Kalbakis K; Christophylakis C; Kalykaki A; Vamvakas L; Kotsakis A; Agelaki S; Diamandidou E; Touroutoglou N; Chatzidakis A; Georgoulias V; Mavroudis D; Souglakos J
    BMC Cancer; 2007 May; 7():91. PubMed ID: 17537235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
    Camacho LH; Garcia S; Panchal AM; Lim J; Hong DS; Ng C; Madoff DC; Fu S; Gayed I; Kurzrock R
    Clin Colorectal Cancer; 2010 Dec; 9(5):311-4. PubMed ID: 21208846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
    Thomas AL; Trarbach T; Bartel C; Laurent D; Henry A; Poethig M; Wang J; Masson E; Steward W; Vanhoefer U; Wiedenmann B
    Ann Oncol; 2007 Apr; 18(4):782-8. PubMed ID: 17218488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
    Sharma S; Abhyankar V; Burgess RE; Infante J; Trowbridge RC; Tarazi J; Kim S; Tortorici M; Chen Y; Robles RL
    Ann Oncol; 2010 Feb; 21(2):297-304. PubMed ID: 19940012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.